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Purpose: To assess clinical efﬁcacy of deep brain stimulation (DBS) of the pallidum in
Myoclonus–Dystonia (M–D) patients, and to compare pre- and post-operative striatal
dopamine D2 receptor availability. Methods: Clinical parameters were scored using val-
idated rating scales for myoclonus and dystonia. Dopamine D2 receptor binding of three
patients was studied before surgery and approximately 2 years post-operatively using 123-
I-iodobenzamide Single Photon Emission ComputedTomography.Two patients who did not
undergo surgery served as controls. Results: Clinically, the three M–D patients improved
83, 17, and 100%, respectively on the myoclonus rating scale and 78, 23, and 65% on
the dystonia rating scale after DBS. Dopamine D2 receptor binding did not change after
surgery. In the two control subjects, binding has lowered further. Conclusion:These ﬁnd-
ings conﬁrm that DBS of the pallidum has beneﬁcial effects on motor symptoms in M–D
and suggest this procedure might stabilize dopamine D2 receptor binding.
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INTRODUCTION
Myoclonus–Dystonia (M–D) is a movement disorder clinically
characterized by myoclonic jerks and dystonic postures or move-
ments of the upper body, often combined with psychiatric
symptoms such as depressed mood or anxiety (Zimprich et al.,
2001). M–D is autosomal dominantly inherited and is frequently
caused by mutations in the epsilon-sarcoglycan gene (SGCE)
on chromosome 7q21 (DYT-11; Klein, 2003; Asmus and Gasser,
2004).
Deep brain stimulation (DBS) of the globus pallidus internus
(GPi) is currently the most promising technique for treatment
of patients with severe medically refractory dystonia. Three ran-
domized controlled trials investigated this procedure in primary
generalized dystonia and found signiﬁcant clinical improvement
on the Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS)
after 6 and 12months (Vidailhet et al., 2005; Kupsch et al., 2006;
Valldeoriola et al., 2010), sustained after a 3-year follow up period
(Vidailhet et al., 2007). More speciﬁcally on M–D, a recent study
of GPi-DBS in ﬁve M–D patients found striking beneﬁcial effects
on dystonia and particularly on myoclonus (Azoulay-Zyss et al.,
2011) as did another study, comparing GPi-DBS and thalamic
nucleus ventralis intermedius (VIM)-DBS in 10 M–D patients
with either target (Gruber et al., 2010). Additional case reports
describe good response of motor symptoms after VIM-DBS or
GPi-DBS in M–D patients (Cif et al., 2004; Foncke et al., 2007;
Kuncel et al., 2009; Kurtis et al., 2010). To summarize, GPi-DBS
has been reported in only 19 M–D patients so far and positive
results were reported, although no class I or II trial has been
reported.
Neuronal models of dystonia have postulated hyperactivity of
the direct putamen–pallidal pathway with reduced inhibitory out-
put of the internal segment of the globus pallidus (GPi), with
subsequently increased thalamic input to the (pre-) motor cortex,
resulting in excessive motor cortex excitation (Vitek, 2002). Pre-
viously, our group showed statistically signiﬁcantly lower striatal
dopamine D2 receptor (D2R) binding in M–D patients, possibly
due to decreased D2R availability or increased levels of endoge-
nous dopamine and consequently competitive D2R occupancy
(Beukers et al., 2009), consistent with a mouse model showing
increased striatal dopamine and metabolites in SGCE knockout
mice (Yokoi et al., 2006).
In Parkinson’s disease several studies regarding the effect of
DBS on D2R have been published (Abosch et al., 2003; Hilker
et al., 2003; Hesse et al., 2008). Acute stimulation (stimulator
on versus off) of the subthalamic nucleus (STN) did not induce
sufﬁcient endogenous dopamine to inﬂuence D2R binding signif-
icantly (Abosch et al., 2003; Yokoi et al., 2006; Hesse et al., 2008).
Hesse and co-workers showed a statistically signiﬁcant increase of
IBZM binding to D2R after STN-DBS (pre- versus post-surgery;
stimulator on; Abosch et al., 2003). However, the opposite was
found after GPi-DBS (Nakajima et al., 2003). To our knowledge,
studies comparing D2R availability before and after DBS have
never been performed in any type of dystonia. The ﬁrst aim of
this study is to report the clinical effects of GPi-DBS on M–D
patients who had surgery in our center. Moreover, as our previous
study showed decreased striatal receptor binding in M–D patients
(Vidailhet et al., 2005), our second aim was to examine whether
D2R may increase (reﬂecting normalization) after GPi-DBS.
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MATERIALS AND METHODS
PATIENTS
Three male M–D patients (ages 29, 48, and 48 years) at the time of
the ﬁrst single photon emission computed tomography (SPECT)
scan, in whom the DYT-11 mutation was genetically conﬁrmed
(1 basepair insertion: 885Tins, 304 C>T and 619–620 delAG,
respectively), were studied using [123-I]-IBZM SPECT before
and approximately 2 years after bilateral simultaneous GPi DBS
implant. Surgery was performed under local anesthesia, with the
use of intraoperative microelectrode recordings and test stimula-
tion. Post-operative CT-scans were co-registered with the frame-
based pre-operative MRI to conﬁrm positioning of the electrodes
in the GPi. The pre-operative [123-I]-IBZM SPECT scans of these
3 patients and of 12 other mutation-positive M–D patients were
reported previously (Beukers et al., 2009). From this same study
population, two genetically conﬁrmed M–D patients who had not
receivedDBS agreed to be re-scanned after approximately 3.5 years
to serve as controls (both mutation 619–620 delAG, related to sub-
ject 3). None of the patients had a history of neuroleptic drug
usage or any other dopamine receptor blocking agent. Dystonia
and myoclonus were assessed at the time of the ﬁrst and sec-
ond scan using the BFMDRS (Burke et al., 1985) and the Uniﬁed
Myoclonus Rating Scale (Frucht et al., 2002). Subject 2 was the
only one who had received Botulinum toxin injection in cervi-
cal muscles approximately 9weeks prior to the ﬁrst scan; for this
reason, in this subject the myoclonus and dystonia scores of his
pre-operative assessment were used approximately 3months after
his last botulinum toxin injection. Patient characteristics and time-
frames of scanning are summarized in Table 1. All subjects gave
written informed consent and the study was approved by the local
medical ethics committee.
DATA ACQUISITION
The IBZM-SPECT methods, for data acquisition and processing
were identical for all scans (Beukers et al., 2009). Shortly, subjects
received a potassium iodide solution to block thyroid uptake of
free radioactive iodide. Approximately 100MBq of [123-I]-IBZM
was given intravenously as bolus, followed by continuous infusion
of 25MBq/h to achieve unchanging regional brain activity levels
(Laruelle et al., 1995; Booij et al., 1997). Acquisition of the images
was started 2 h after the bolus injection (Frucht et al., 2002).
Single photon emission computed tomography studies were
performed using a 12-detector single slice brain-dedicated scanner
(Neurofocus 810, which is an upgrade of the Strichmann Medical
Equipment).
DATA PROCESSING
Attenuation correction of all images was performed (Ishibashi
et al., 2009). Images were reconstructed in 3D mode
(http://www.neurophysics.com). These 3D reconstructed images
were then randomly numbered by an independent physician and
analyzed blindly by one observer (R. J. Beukers). For quantiﬁca-
tion, a region-of-interest (ROI) analysis was performed. For analy-
sis of striatal [123-I]-IBZM binding, the ratio of speciﬁc striatal
to occipital binding (representing non-speciﬁc binding) was cal-
culated by averaging four transverse slices, representing the most
intense striatal binding. Standard templates with ﬁxed ROIs were
manually placed on the striatum and occipital cortex, and then
the ratio of striatal to occipital binding (SOR) was calculated as
follows: (total striatal binding− occipital binding)/occipital bind-
ing. The analyses of the 3D reconstructed images was performed
again the following week, variability and the intraclass correlation
coefﬁcient were then calculated to assess intra-observer reliability.
DATA ANALYSIS
Symmetry of the left and right SORs was calculated using a
Wilcoxon signed ranks test in all patients, this analysis was per-
formed using SPSS version 17. Because the number of patients is
too small to perform meaningful statistics between groups, none
were calculated. Instead, all data is presented in Tables 1 and 2. All
videos used to assess the UMRS and BFMDRS were scored by a
movement disorder specialist (J. D. Speelman).
RESULTS
CLINICAL CHARACTERISTICS
Patient characteristics are summarized in Table 1. The patients
who underwent DBS all reported signiﬁcant improvement of their
symptoms at the time of the second [123-I]-IBZM SPECT scan.
Table 1 | Clinical characteristics.
N M/F Age BFMDRS/UMRS at first
scan (before GPi-DBS)
BFMDRS/UMRS at second
scan (after GPi-DBS)
% Change Stimulation
settings L/R
Time after
GPi DBS
Time between
scans (months)
1 M 29 18/46 4/8 −78/−83 3.5V 120 us/130Hz 27months 30
2.8V 90 us/130Hz
2 M 48 26/70* 20/58 −23/−17 3.2V 60 us/130Hz 12months 28
3.0V 60 us/130Hz
3 M 48 20/100 7/0 −65/−100 3.0V 60 us/130Hz 19months 29
BFMDRS/UMRS at ﬁrst
scan
BFMDRS/UMRS at second
scan
–
4 M 53 4/4 4/4 0/0 – No DBS 43
5 M 51 26/12 6/10 −77/−17 – No DBS 46
N, subject; M, male; BFMDRS, Burke Fahn Marsden Dystonia Rating Scale; UMRS, Uniﬁed Myoclonus Rating Scale; GPi-DBS, globus pallidus internus deep brain
stimulation; age, age at time of ﬁrst [123-I]-IBZM SPECT scan. *Scoring performed before DBS, 15months after ﬁrst scan.
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Table 2 | SORs before and after GPi-DBS.
Subject Before GPi-DBS After GPi-DBS
SOR left SOR right SOR mean SOR left SOR right SOR mean
1 0.90 0.85 0.87 0.83 0.89 0.86
2 1.06 0.90 0.98 1.21 1.07 1.14
3 1.04 1.06 1.05 0.86 0.93 0.89
No DBS, ﬁrst scan No DBS, second scan
4 1.14 1.14 1.14 0.93 0.82 0.87
5 1.05 0.94 1.00 0.66 0.73 0.69
GPi-DBS, globus pallidus internus deep brain stimulation; SOR, striatal to occipital ratio.
When formally scored on video, GPi-DBS patients had improved
78,23,and 65%,respectively on theBFMDRSand83,17,and 100%
on the UMRS. One patient not having undergone DBS improved
on the BFMDRS (77%) and on theUMRS (17%), the other patient
showed no change on the clinical rating scales.
[123-I]-IBZM SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY
Variability between the two analyses performed with a 1-week
interval was 3.7%, with an intraclass correlation coefﬁcient of
93.5%. Results of second analysis are presented in Table 2. No
asymmetry between left and right SORs was found, either at the
ﬁrst or at the second scan (ﬁrst scan p = 0.50; second scan p = 0.69
respectively). No consistent differences between the measurement
before and after DBS are discernable (SOR mean: one unchanged,
one higher, one lower). Of both subjects who did not have DBS,
the mean SOR was lower after surgery compared to before surgery.
DISCUSSION
Globus pallidus internus-DBS improved greatly myoclonus and,
to a lesser extent dystonia, consistent with earlier studies (Gruber
et al., 2010; Azoulay-Zyss et al., 2011). In our previous study, we
found decreased D2R in 15 M–D patients, possibly reﬂecting an
increase in endogenous striatal dopamine (Beukers et al., 2009).
In this study, no large effect of GPi-DBS on D2R binding poten-
tial in M–D patients was observed despite obvious clinical beneﬁt
on myoclonus and dystonia rating scales. This lack of change is
consistent with studies regarding STN-DBS in Parkinson’s disease,
but not consistent with the GPi-DBS study describing normaliza-
tion (decrease) of D2R binding potential in Parkinson’s disease. A
drawback of this study is the small number of patients, rendering
it impossible to reach statistical signiﬁcance. It was not our inten-
tion to reach a predeﬁned level of signiﬁcance as much as it was to
report an interesting ﬁnding. Of course, a much larger sample size
is needed to warrant ﬁrmer conclusions. However, interestingly,
in both M–D patients who did not had surgery, a clear decrease
of D2R binding was observed. The changes on the clinical rat-
ing scales in patient 5 might be attributed to symptom variability
over time or variable effect of medication. In addition, this patient
reported being very anxious at the time of the ﬁrst video-scoring
and concomitant worsening of his motor symptoms. At the time
of the second video-scoring, the patient reported being much less
anxious, while medication had not changed in the mean time.
Progression of M–D could be associated with a further decline
of D2R, which may be mitigated by DBS of the GPi. Although in
our previous study we did not ﬁnd an association between dis-
ease severity and D2R across patients, this might be true for the
individual patient. The decline of SORs in non-operated patients
is faster than the 5% per decade previously reported in the litera-
ture in normal subjects (Laruelle et al., 1995); for this reason it is
unlikely that the slightly longer time interval between the ﬁrst and
second scan in this group is the cause of the lowered D2R bind-
ing. Future imaging studies on the effects of disease progression
and the effects of DBS in larger groups of M–D patients having
undergone and not having undergone DBS are needed to test this
hypothesis.
In conclusion, this study conﬁrms the clinical efﬁcacy of GPi-
DBS in M–D, that is not paralleled by any discernable changes
on the dopaminergic pathways as measured with [123-I]-IBZM
SPECT. In non-operated M–D patients D2R binding seems to
have lowered even further, possibly reﬂecting a stabilizing effect of
GPi-DBS on the dopaminergic pathways.
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